A phase I/II study of induction oxaliplatin, 5FU chemoradiation in patients with locally advanced, unresectable pancreatic cancer

被引：0
|
作者：
Leung, R. C. [1 ]
Ryan, T. [1 ]
Hochster, H. [1 ]
Newman, E. [1 ]
Chandra, A. [1 ]
机构：
[1] NYU, Med Ctr, New York, NY 10016 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15027
引用
收藏
页数：2
相关论文
共 50 条
  • [21] LEOPARD-II: A randomized phase II study of radiochemotherapy (RCT) with 5FU and cisplatin plus/minus cetuximab (Cet) in unresectable locally advanced esophageal cancer (LAEC).
    Rades, Dirk
    Moehler, Markus Hermann
    Debus, Juergen
    Belka, Claus
    Homann, Nils
    Petersen, Cordula
    Ridwelski, Karsten
    Reyes, Renato
    Kranich, Anne L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [22] Phase I Study of Chemoradiation Therapy (nab-Paclitaxel/Gemcitabine) in 18 Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma
    Ioka, Tatsuya
    Katayama, Kazuhiro
    Hibino, Kenji
    Yutaro, Abe
    Tamura, Takeshi
    Takada, Ryoji
    Fukutake, Nobuyasu
    Ashida, Reiko
    Ohkawa, Kazuyoshi
    Akita, Hiroshi
    Takahashi, Hidenori
    Hirata, Takero
    Teshima, Teruki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 147 - 147
  • [23] Phase II study of preoperative chemoradiation with S-1 plus oxaliplatin in patients with locally advanced rectal cancer
    Lee, Eun Mi
    Hong, Yong Sang
    Kim, Kyu-pyo
    Lee, Jae-Lyun
    Kim, Sun Young
    Park, Young Suk
    Choi, Doo Ho
    Kim, Jong Hoon
    Lim, Seok-Byung
    Yu, Chang Sik
    Kim, Jin Cheon
    Lee, Ju Hee
    Kim, Ah Young
    Kim, Tae Won
    CANCER SCIENCE, 2013, 104 (01) : 111 - 115
  • [24] PHASE I STUDY OF PREOPERATIVE CHEMORADIATION WITH S-1 AND OXALIPLATIN IN PATIENTS WITH LOCALLY ADVANCED RESECTABLE RECTAL CANCER
    Hong, Yong Sang
    Lee, Jae-Lyun
    Park, Jin Hong
    Kim, Jong Hoon
    Yoon, Sang Nam
    Lim, Seok-Byung
    Yu, Chang Sik
    Kim, Mi-Jung
    Jang, Se-Jin
    Lee, Jung Shin
    Kim, Jin Cheon
    Kim, Tae Won
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 79 (03): : 684 - 689
  • [25] Preoperative chemoradiation in locally advanced pancreatic carcinoma: A phase II study
    Brunner, TB
    Grabenbauer, GG
    Kastl, S
    Herrmann, O
    Baum, U
    Fietkau, R
    Klein, P
    Bautz, W
    Schneider, T
    Hohenberger, W
    Sauer, R
    ONKOLOGIE, 2000, 23 (05): : 436 - 442
  • [26] 'Tomudex' (raltitrexed) plus 5FU combination treatment for patients with advanced colorectal cancer: a Phase I study
    Mayer, S
    Hilger, R
    Muller, C
    Dohmen, D
    Kloeppel, R
    Vanhoefer, U
    Scheulen, ME
    Seeber, S
    Harstick, A
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S74 - S74
  • [27] Phase I study of chemoradiation therapy (nab-paclitaxel/Gemcitabine) in 15 patients with unresectable locally advanced pancreatic cancer (UR-LAPC).
    Sueyoshi, Hironari
    Ioka, Tatsuya
    Tamura, Takeshi
    Takada, Ryoji
    Fukutake, Nobuyasu
    Ashida, Reiko
    Ohkawa, Kazuyoshi
    Takahashi, Hidenori
    Teshima, Teruki
    Katayama, Kazuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [28] Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients
    Ducreux, M
    Mitry, E
    Ould-Kaci, M
    Boige, V
    Seitz, JF
    Bugat, R
    Breau, JL
    Bouchè, O
    Etienne, PL
    Tigaud, JM
    Morvan, F
    Cvitkovic, E
    Rougier, P
    ANNALS OF ONCOLOGY, 2004, 15 (03) : 467 - 473
  • [29] A PHASE III STUDY OF ADRIAMYCIN + 5FU VS BCNU + ADRIAMYCIN + FTORAFUR FOR PATIENTS WITH ADVANCED PANCREATIC-CANCER
    FRIEDMAN, MA
    CASSIDY, MJ
    HANNIGAN, JF
    GRIBBLE, M
    TORTI, FM
    REYNOLDS, RD
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1981, 22 (MAR): : 156 - 156
  • [30] Chemoradiation for Locally Advanced Unresectable Pancreatic Cancer-What Now?
    Vaccaro, Gina
    Lopez, Charles D.
    JAMA ONCOLOGY, 2017, 3 (06) : 850 - 851
12345